{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T05:11:59Z","timestamp":1694063519394},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1684","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Talquetamab-tgvs (Talvey \u2013 Janssen), a bispecific GPRC5D-directed T-cell engager, has been granted accelerated approval by the FDA for treatment of relapsed or refractory multiple myeloma in adults who received \u22654 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.<\/jats:p>","DOI":"10.58347\/tml.2023.1684e","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T15:47:34Z","timestamp":1694015254000},"page":"e149-e150","source":"Crossref","is-referenced-by-count":0,"title":["Talquetamab (Talvey) for Multiple Myeloma"],"prefix":"10.58347","volume":"65","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2023,9,4]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T15:47:34Z","timestamp":1694015254000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1684e"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":0,"journal-issue":{"issue":"1684","published-online":{"date-parts":[[2023,9,4]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2023.1684e","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]}}}